What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Pharmacology
- Acquired immunodeficiency syndrome
His main research concerns Pharmacology, Pharmacokinetics, Internal medicine, Ritonavir and Indinavir.
His Pharmacology research incorporates elements of Antibiotics and Reverse-transcriptase inhibitor.
His work carried out in the field of Reverse-transcriptase inhibitor brings together such families of science as Lamivudine, Emtricitabine, Efavirenz and Confidence interval.
His Pharmacokinetics research integrates issues from Antibacterial agent, Rifampicin, Blood plasma and Dosing.
The Internal medicine study combines topics in areas such as Gastroenterology, Immunology, Viral load and Nevirapine.
His Ritonavir study incorporates themes from High-performance liquid chromatography, Chromatography, Lopinavir, HIV Protease Inhibitor and Atazanavir.
His most cited work include:
- Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel (2345 citations)
- Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. (767 citations)
- Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents (268 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Pharmacokinetics, Pharmacology, Internal medicine, Ritonavir and Gastroenterology.
His Pharmacokinetics research is multidisciplinary, relying on both Adverse effect, Pharmacotherapy, Zidovudine and Dosing.
His research integrates issues of Lamivudine, Efavirenz and Indinavir in his study of Pharmacology.
His research in Lamivudine tackles topics such as Nevirapine which are related to areas like Reverse-transcriptase inhibitor.
His study on Internal medicine also encompasses disciplines like
- Viral load that intertwine with fields like Pregnancy,
- Immunology which connect with Acquired immunodeficiency syndrome.
His work investigates the relationship between Ritonavir and topics such as Lopinavir that intersect with problems in Lopinavir/ritonavir.
He most often published in these fields:
- Pharmacokinetics (48.57%)
- Pharmacology (45.52%)
- Internal medicine (36.38%)
What were the highlights of his more recent work (between 2018-2021)?
- Pharmacokinetics (48.57%)
- Internal medicine (36.38%)
- Dosing (11.47%)
In recent papers he was focusing on the following fields of study:
David M. Burger mainly focuses on Pharmacokinetics, Internal medicine, Dosing, Gastroenterology and Drug.
His Pharmacokinetics research is multidisciplinary, incorporating perspectives in Pregnancy, Dolutegravir and Urology.
His biological study spans a wide range of topics, including Randomized controlled trial, Efavirenz, Pharmacology, Raltegravir and Pediatrics.
His research in Internal medicine intersects with topics in Oncology and Ritonavir.
In his study, Lopinavir/ritonavir is inextricably linked to Lopinavir, which falls within the broad field of Ritonavir.
His studies deal with areas such as Hepatitis B, Comorbidity and Intensive care medicine as well as Drug.
Between 2018 and 2021, his most popular works were:
- Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. (24 citations)
- Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors. (20 citations)
- Dose recommendations for anticancer drugs in patients with renal or hepatic impairment (19 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Acquired immunodeficiency syndrome
- Cancer
David M. Burger spends much of his time researching Pharmacokinetics, Internal medicine, Drug, Pregnancy and Dolutegravir.
His Pharmacokinetics study combines topics in areas such as Rifampicin, Renal replacement therapy, Disease, Dosing and Pharmacometrics.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Oncology and Therapeutic index.
His study in Dolutegravir is interdisciplinary in nature, drawing from both Therapeutic drug monitoring, Randomized controlled trial, Lamivudine, Univariate analysis and Raltegravir.
Many of his studies involve connections with topics such as Pharmacology and Antibiotics.
His work deals with themes such as In vivo and In vitro experiment, which intersect with Pharmacology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
